Key result
Targeting purinergic signaling pathways shows promise for mitigating perioperative ischemia-reperfusion injury.
Why the study?
Perioperative ischemia–reperfusion injury remains a significant cause of postoperative organ dysfunction and mortality after cardiac, vascular, transplant, and high-risk noncardiac surgery, yet practical preventive strategies remain limited. Purinergic signaling centrally regulates inflammation, microvascular function, and tissue recovery during perioperative ischemia and reperfusion.
Do pharmacological strategies targeting purinergic signaling pathways provide organ protection against perioperative ischemia–reperfusion injury in patients undergoing high-risk surgery?
Do pharmacological strategies targeting purinergic signaling pathways provide organ protection against perioperative ischemia–reperfusion injury in patients undergoing high-risk surgery?
This narrative review synthesizes mechanistic and translational evidence demonstrating that targeting purinergic signaling pathways (such as enhancing adenosine generation or inhibiting ATP-P2X7-driven inflammation) is a promising pharmacological strategy for preventing perioperative ischemia–reperfusion injury across multiple organ systems.
Answers are grounded in this paper and cite their sources.
Insufficient clinical evidence precludes routine use of purinergic modulators; extends preclinical targets for perioperative ischemia-reperfusion protection.
Background Perioperative ischemia–reperfusion injury (IRI) remains a significant cause of postoperative organ dysfunction and mortality after cardiac, vascular, transplant, and high-risk noncardiac surgery. Despite advances in anesthetic and surgical techniques, practical strategies to prevent IRI are limited. Growing evidence indicates that purinergic signaling, mediated by extracellular ATP, ADP, adenosine, and their receptors, centrally regulates inflammation, microvascular function, and tissue recovery during perioperative ischemia and reperfusion. Methods This narrative review synthesizes preclinical, translational, and clinical evidence on purinergic mechanisms in perioperative IRI across major organ systems, including the heart, lungs, kidneys, liver, intestines, and brain, emphasizing pharmacological strategies and anesthetic interactions relevant to intraoperative and early postoperative management. Results During ischemia and early reperfusion, extracellular ATP released from injured cells activates P2 receptors, promoting inflammasome activation, endothelial dysfunction, and microcirculatory injury. Subsequent hydrolysis of ATP by ectonucleotidases CD39 and CD73 generates adenosine, which activates P1 receptors (Adora1, Adora2a, Adora2b, and Adora3) to suppress inflammation, improve perfusion, and enhance tissue protection. Hypoxia-inducible factor (HIF)-dependent upregulation of CD73 and A2B transcriptionally amplifies this ATP-to-adenosine transition, and miRNAs post-transcriptionally modulate it. Pharmacological approaches targeting these pathways represent promising strategies for perioperative organ protection, whereas clinical evidence supporting anesthetic regimen selection for purinergic modulation remains insufficient. The efficacy of conditioning strategies, including ischemic preconditioning and remote ischemic preconditioning (RIPC), remains controversial, with negative large-scale trials highlighting the translational gap between preclinical models and multimorbid surgical patients. Conclusions Purinergic signaling provides a unifying mechanistic framework for perioperative ischemia–reperfusion injury and represents a promising target for pharmacological organ protection. Prioritize pharmacological strategies that enhance adenosine generation, activate protective adenosine receptors, or inhibit ATP-P2X7-driven inflammation in perioperative clinical trials. Understanding how comorbidities and concomitant medications modulate purinergic pathways is essential for successful clinical translation.
No takes yet. Share an insight, caveat, or question.
Echeverria-Villalobos et al. (2026) conducted a review in Perioperative ischemia-reperfusion injury. Pharmacological strategies targeting purinergic signaling (CD39, CD73, P1/P2 receptors) was evaluated on Perioperative organ protection and ischemia-reperfusion injury. Pharmacological strategies enhancing CD39/CD73-mediated adenosine generation, activating P1 receptors, or inhibiting P2X7-driven inflammation represent promising targets for perioperative IRI.
Synapse has enriched 10 related papers. Consider them for comparative context: